Skip to main content
. 2013 May 31;2013(5):CD004525. doi: 10.1002/14651858.CD004525.pub2

Comparison 44. Adverse events within two years: etanercept vs. disease‐modifying anti‐rheumatic drug (DMARD).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Total 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.37 [1.10, 1.70]
1.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.37 [1.10, 1.70]
2 Abdominal pain 2 604 Risk Ratio (M‐H, Random, 95% CI) 1.85 [0.21, 16.14]
2.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Random, 95% CI) 1.85 [0.21, 16.14]
3 Asthenia 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.68, 1.90]
3.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.68, 1.90]
4 Accidental injury 2 604 Risk Ratio (M‐H, Random, 95% CI) 2.04 [0.20, 20.68]
4.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Random, 95% CI) 2.04 [0.20, 20.68]
5 Arthralgia 2 604 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.39, 2.50]
5.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Random, 95% CI) 0.98 [0.39, 2.50]
6 Back pain 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 1.29 [0.85, 1.95]
6.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 1.29 [0.85, 1.95]
7 Bronchitis 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 2.55 [0.92, 7.03]
7.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 2.55 [0.92, 7.03]
8 Diarrhoea 2 604 Risk Ratio (M‐H, Random, 95% CI) 2.32 [0.20, 26.32]
8.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Random, 95% CI) 2.32 [0.20, 26.32]
9 Dyspepsia 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 3.40 [0.80, 14.38]
9.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 3.40 [0.80, 14.38]
10 Flu syndrome 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 4.37 [1.05, 18.10]
10.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 4.37 [1.05, 18.10]
11 Gingival/dental infection 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.70 [0.37, 7.88]
11.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.70 [0.37, 7.88]
12 Headache 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.72, 1.57]
12.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 1.06 [0.72, 1.57]
13 Hypertension 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 2.47 [1.29, 4.72]
13.1 Etanercept 25 mg SC twice weekly 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 2.47 [1.29, 4.72]
14 Increased cough 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 0.79 [0.47, 1.32]
14.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 0.79 [0.47, 1.32]
15 Infections (total) 2 604 Risk Ratio (M‐H, Random, 95% CI) 1.26 [0.67, 2.38]
15.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Random, 95% CI) 1.26 [0.67, 2.38]
16 Injection site haemorrhage 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.35, 2.69]
16.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.35, 2.69]
17 Injection site reaction 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 9.00 [4.21, 19.24]
17.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 9.00 [4.21, 19.24]
18 Malignancy 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 2.53 [0.60, 10.63]
18.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 2.53 [0.60, 10.63]
19 Miscellaneous skin infections 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 19.13 [1.18, 310.46]
19.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 19.13 [1.18, 310.46]
20 Nausea 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.24, 0.49]
20.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.24, 0.49]
21 Pain 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 1.12 [0.64, 1.96]
21.1 Etanercept 25 mg SC twice weekly 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 1.12 [0.64, 1.96]
22 Paraesthesia 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.94 [0.22, 16.92]
22.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.94 [0.22, 16.92]
23 Pharyngitis or laryngitis 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 3.88 [1.23, 12.29]
23.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 3.88 [1.23, 12.29]
24 Rash 2 604 Risk Ratio (M‐H, Random, 95% CI) 1.15 [0.34, 3.95]
24.1 Etanercept 25 mg SC twice weekly 2 604 Risk Ratio (M‐H, Random, 95% CI) 1.15 [0.34, 3.95]
25 Rheumatoid arthritis 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 8.25 [2.06, 32.98]
25.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 8.25 [2.06, 32.98]
26 Serious infections 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.47, 1.93]
26.1 Etanercept 25 mg SC twice weekly 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.47, 1.93]
27 Sinusitis 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
27.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 12.26 [0.74, 202.98]
28 Upper respiratory tract infection 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
28.1 Etanercept 25 mg SC twice weekly 1 153 Risk Ratio (M‐H, Fixed, 95% CI) 1.41 [0.75, 2.65]
29 Vomiting 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 0.32 [0.16, 0.63]
29.1 Etanercept 25 mg SC twice weekly 1 451 Risk Ratio (M‐H, Fixed, 95% CI) 0.32 [0.16, 0.63]